Jian-Jun Zhao,Jianhong Lin,Di Zhu,Xujun Wang,Daniel Brooks,Ming Chen,Zhang-Bo Chu,Kohichi Takada,Bryan Ciccarelli,Samir Admin,Jianguo Tao,Yu-Tzu Tai,Steven Treon,Geraldine Pinkus,Winston Patrick Kuo,Teru Hideshima,Mary Bouxsein,Nikhil Munshi,Kenneth Anderson,Ruben Carrasco

Abstract:Wnt/β-catenin signaling underlies the pathogenesis of a broad range of human cancers, including the deadly plasma cell cancer multiple myeloma. In this study, we report that downregulation of the tumor suppressor microRNA miR-30-5p is a frequent pathogenetic event in multiple myeloma. Evidence was developed that miR-30-5p downregulation occurs as a result of interaction between multiple myeloma cells and bone marrow stromal cells, which in turn enhances expression of BCL9, a transcriptional coactivator of the Wnt signaling pathway known to promote multiple myeloma cell proliferation, survival, migration, drug resistance, and formation of multiple myeloma cancer stem cells. The potential for clinical translation of strategies to re-express miR-30-5p as a therapeutic approach was further encouraged by the capacity of miR-30c and miR-30 mix to reduce tumor burden and metastatic potential in vivo in three murine xenograft models of human multiple myeloma without adversely affecting associated bone disease. Together, our findings offer a preclinical rationale to explore miR-30-5p delivery as an effective therapeutic strategy to eradicate multiple myeloma cells in vivo.

Supplementary Materials and Methods, Figure Legends from miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 Pathway

Supplementary Table 1 from miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 Pathway

Supplementary Figure 1 from miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 Pathway

Supplementary Figure 2 from miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 Pathway

Supplementary Figure 4 from miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 Pathway

Supplementary Figure 3 from miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 Pathway

Supplementary Materials and Methods from Loss of SNAIL Regulated Mir-128-2 on Chromosome 3p22.3 Targets Multiple Stem Cell Factors to Promote Transformation of Mammary Epithelial Cells

Supplemental Materials and Methods from KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis

Supplementary Table 2 from Survivin Expression Is Differentially Regulated by a Selective Cross-talk between RBM38 and miRNAs let-7b or miR-203a

Supplementary Figure Legends 1-6, Methods from Pivotal Role of Reduced <i>let-7g</i> Expression in Breast Cancer Invasion and Metastasis

miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway.

Supplementary Materials and Methods and Supplementary Figure Legends from Mir200c Attenuates P-gp–Mediated MDR and Metastasis by Targeting JNK2/c-Jun Signaling Pathway in Colorectal Cancer

Supplementary Figures 1-6 from Pivotal Role of Reduced <i>let-7g</i> Expression in Breast Cancer Invasion and Metastasis

Biological Functions and Molecular Mechanisms of MiR-608 in Cancer

Supp Table S1, S3-8 from Integrated Genomic and Functional Microrna Analysis Identifies Mir-30-5p As a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer

Supplementary Materials and Methods from DNMT1–MicroRNA126 Epigenetic Circuit Contributes to Esophageal Squamous Cell Carcinoma Growth via ADAM9–EGFR–AKT Signaling

Supplementary Figures 1-6 from Loss of SNAIL Regulated Mir-128-2 on Chromosome 3p22.3 Targets Multiple Stem Cell Factors to Promote Transformation of Mammary Epithelial Cells

Supplementary Figure 4 from DNA Methylation-Mediated Repression of Mir-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer